American Journal of Cardiovascular Drugs

, Volume 16, Issue 4, pp 275–284 | Cite as

Drug Interaction Between Clopidogrel and Ranitidine or Omeprazole in Stable Coronary Artery Disease: A Double-Blind, Double Dummy, Randomized Study

  • Remo Holanda de Mendonça FurtadoEmail author
  • Robert Patrick Giugliano
  • Celia Maria Cassaro Strunz
  • Cyrillo Cavalheiro Filho
  • José Antonio Franchini Ramires
  • Roberto Kalil Filho
  • Pedro Alves Lemos Neto
  • Alexandre Costa Pereira
  • Tânia Rúbia Rocha
  • Beatriz Tonon Freire
  • Elbio Antonio D’Amico
  • José Carlos Nicolau
Original Research Article



Proton-pump inhibitors (PPIs) are often prescribed to patients receiving dual antiplatelet therapy (DAPT). However, this class of medication, especially omeprazole, has been associated with a reduction in clopidogrel efficacy, leading many clinicians to substitute omeprazole with ranitidine.


Our objective was to compare the antiplatelet effect of clopidogrel before and after the addition of omeprazole or ranitidine.


We measured platelet aggregability at baseline and after 1 week of clopidogrel 75 mg daily. Subjects were then randomized in a double-blinded, double-dummy fashion to omeprazole 20 mg twice daily (bid) or ranitidine 150 mg bid. We repeated aggregability tests after 1 additional week, using VerifyNow P2Y12™ (Accumetrics; San Diego, CA, USA), depicting aggregability as percent inhibition of platelet aggregation (IPA).


We enrolled 41 patients in the omeprazole group and 44 in the ranitidine group. IPA was significantly decreased after the addition of omeprazole to clopidogrel (from 26.3 ± 32.9 to 17.4 ± 33.1 %; p = 0.025), with no statistical significant changes observed in the ranitidine group (from 32.6 ± 28.9 to 30.1 ± 31.3 %; p = 0.310). The comparison of IPA in both groups at the end of the follow-up showed a trend toward significance (p = 0.07, 95 % confidence interval [CI] −1.19 to 26.59); after excluding homozygous patients for 2C19*2 genotype, the comparison of IPA between the groups reached statistical significance (32.7 ± 30.8 vs. 17.7 ± 33.4 %, respectively, for ranitidine and omeprazole groups; p = 0.04).


Unlike omeprazole, ranitidine did not influence platelet aggregability response to clopidogrel.

Clinical Trial Registration



Percutaneous Coronary Intervention Acute Coronary Syndrome Clopidogrel Omeprazole Atorvastatin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors thank Paul A Gurbel (Sinai Center for Thrombosis Research, Baltimore, MD, USA) and Marco Cattaneo (University of Milan, Milan, Italy) for their contribution to the study protocol.

Author contributions

JC Nicolau and RHM Furtado: conception, analysis and interpretation of data, drafting the manuscript; RP Giugliano: analysis and interpretation of data, drafting the manuscript; CMC Strunz, C Cavalheiro Filho, AC Pereira, EA D´Amico, JAF Ramires, R Kalil Filho, PA.Lemos Neto, TR Rocha, BT Freire: critically revised the manuscript and made important contributions to its final format.

Compliance with Ethical Standards

Our protocol is in accordance with the recommendations of the Helsinki Declaration and Good Clinical Practice norms on medical research in humans. The Heart Institute Ethics Committee approved the protocol before study inclusion began. All patients signed an ICF before participating in the protocol. All authors fulfilled conflict of interest disclosure forms.


This study was financially supported by the São Paulo Research Foundation (FAPESP), process #2010/16324-1. The funder did not participate in protocol design, study conduct, or statistical analysis.


  1. 1.
    Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes. J Am Coll Cardiol. 2014;64:e139–228.CrossRefPubMedGoogle Scholar
  2. 2.
    O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:e78–140.CrossRefPubMedGoogle Scholar
  3. 3.
    Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569–619.CrossRefPubMedGoogle Scholar
  4. 4.
    Nicolau JC, Timerman A, Marin-Neto JA, et al. Guidelines of Sociedade Brasileira de Cardiologia for unstable angina and non-ST-segment elevation myocardial infarction (II Edition, 2007) 2013–2014 update. Arq Bras Cardiol. 2014;102:1–61.CrossRefPubMedGoogle Scholar
  5. 5.
    Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. J Am Coll Cardiol. 2011;58:e44–122.CrossRefPubMedGoogle Scholar
  6. 6.
    Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–619.CrossRefPubMedGoogle Scholar
  7. 7.
    Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.CrossRefPubMedGoogle Scholar
  8. 8.
    Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179–89.CrossRefPubMedGoogle Scholar
  9. 9.
    Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607–21.CrossRefPubMedGoogle Scholar
  10. 10.
    Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.CrossRefPubMedGoogle Scholar
  11. 11.
    Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.CrossRefPubMedGoogle Scholar
  12. 12.
    Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908–13.CrossRefPubMedGoogle Scholar
  13. 13.
    Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013;382:614–23.CrossRefPubMedGoogle Scholar
  14. 14.
    Siller-Matula JM, Trenk D, Krähenbühl S, Michelson AD, Delle-Karth G. Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors. J Thromb Haemost. 2014;12:2–14.CrossRefPubMedGoogle Scholar
  15. 15.
    Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (omeprazole clopidogrel aspirin) study. J Am Coll Cardiol. 2008;51:256–60.CrossRefPubMedGoogle Scholar
  16. 16.
    Pham JP, Ueno M, Tello-Montoliu A, et al. Impact of gastric acid-supressing therapies on platelet reactivity in patients with coronary artery disease treated with clopidogrel: results of a pharmacodynamic study. J Am Coll Cardiol. 2011;58:1396–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose: the PACA (proton pump inhibitors and clopidogrel association) prospective randomized study. J Am Coll Cardiol. 2009;54:1149–53.CrossRefPubMedGoogle Scholar
  18. 18.
    Parri MS, Gianetti J, Dushpanova A, et al. Pantoprazole significantly interferes with antiplatelet effect of clopidogrel: results of a pilot randomized trial. Int J Cardiol. 2013;167:2177–81.CrossRefPubMedGoogle Scholar
  19. 19.
    Frelinger AL 3rd, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to asses the effects of dexlansoprazole, lasoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel on healthy volunteers. J Am Coll Cardiol. 2012;59:1304–11.CrossRefPubMedGoogle Scholar
  20. 20.
    O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials. Lancet. 2009;374:989–97.CrossRefPubMedGoogle Scholar
  21. 21.
    Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937–44.CrossRefPubMedGoogle Scholar
  22. 22.
    Nicolau JC, Bhatt DL, Roe MT, et al. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel vs. clopidogrel and managed without revascularization: insights from the TRILOGY ACS trial. Am Heart J. 2015;170:683–94.CrossRefPubMedGoogle Scholar
  23. 23.
    Goodman SG, Clare R, Pieper KS, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from PLATO. Circulation. 2012;125:978–86.CrossRefPubMedGoogle Scholar
  24. 24.
    Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909–17.CrossRefPubMedGoogle Scholar
  25. 25.
    Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration. A systematic meta-analysis. J Am Coll Cardiol. 2010;56:134–43.CrossRefPubMedGoogle Scholar
  26. 26.
    Plavix (clopidogrel bisulfate) tablet. Safety labeling changes approved by FDA Center for Drug Evaluation and Research. Accessed 29 May 2012.
  27. 27.
    Interaction between clopidogrel and proton-pump inhibitors—CHMP updates warning for clopidogrel-containing medicines. Accessed 17 Mar 2010.
  28. 28.
    Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol. 2010;56:2051–66.CrossRefPubMedGoogle Scholar
  29. 29.
    Yun KH, Rhee SJ, Park HY, et al. Effects of omeprazole on the antiplatelet activity of clopidogrel. Int Heart J. 2010;51:13–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010;303:754–62.CrossRefPubMedGoogle Scholar
  31. 31.
    Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015;36:1762–71.CrossRefPubMedGoogle Scholar
  32. 32.
    Aradi D, Storey RF, Komócsi A, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J. 2014;35:209–15.CrossRefPubMedGoogle Scholar
  33. 33.
    Schäfer A, Flierl U, Pförtsch S, Seydelmann N, Micka J, Bauersachs J. The H2-receptor antagonist ranitidine interferes with clopidogrel-mediated P2Y12 inhibition in platelets. Pharmacol Res. 2010;62:352–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849–57.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome P450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354–62.CrossRefPubMedGoogle Scholar
  36. 36.
    Shah NH, LePendu P, Bauer-Mehren A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10:e0124653.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;11:238–46.Google Scholar
  38. 38.
    Angiolillo DJ, Jakubowski JA, Ferreiro JL, et al. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll Cardiol. 2014;64:1005–14.CrossRefPubMedGoogle Scholar
  39. 39.
    Geisler T, Zürn C, Paterok M, et al. Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. Eur Heart J. 2008;29:1635–43.CrossRefPubMedGoogle Scholar
  40. 40.
    Bonaca MP, Bhatt DL, Cohen M, et al. PEGASUS-TIMI 54 Steering Committee and Investigators. N Engl J Med. 2015;372:1791–800.CrossRefPubMedGoogle Scholar
  41. 41.
    Mauri L, Kereiakes DJ, Yeh RW, for the DAPT Study Investigators, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155–66.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
  43. 43.
    Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;5:CD002095. doi: 10.1002/14651858.CD002095.pub5.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Remo Holanda de Mendonça Furtado
    • 1
    Email author
  • Robert Patrick Giugliano
    • 2
  • Celia Maria Cassaro Strunz
    • 1
  • Cyrillo Cavalheiro Filho
    • 1
  • José Antonio Franchini Ramires
    • 1
  • Roberto Kalil Filho
    • 1
  • Pedro Alves Lemos Neto
    • 1
  • Alexandre Costa Pereira
    • 1
  • Tânia Rúbia Rocha
    • 3
  • Beatriz Tonon Freire
    • 1
  • Elbio Antonio D’Amico
    • 3
  • José Carlos Nicolau
    • 1
  1. 1.Heart Institute, University of São Paulo Medical SchoolSão PauloBrazil
  2. 2.Brigham and Women’s Hospital, Harvard Medical SchoolBostonUSA
  3. 3.Clinics Hospital, University of São Paulo Medical SchoolSão PauloBrazil

Personalised recommendations